Current Status of Research on Osteoporosis After Solid Organ Transplantation: Pathogenesis and Management

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2015 Dec 10

PMID 26649301

Citations 16

Authors

Gong-Bin Lan

Xu-Biao Xie

Long-Kai Peng

Lei Liu

Lei Song

He-long Dai

Affiliations

Soon will be listed here.

Abstract

Improved survival following organ transplantation has brought to the forefront some long-term complications, among which osteoporosis and associated fractures are the major ones that adversely affect the quality of life in recipients. The pathogenesis of osteoporosis in transplant recipients is complex and multifactorial which may be related to increased bone resorption, decreased bone formation, or both. Studies have shown that the preexisting underlying metabolic bone disorders and the use of immunosuppressive agents are the major risk factors for osteoporosis and fractures after organ transplantation. And rapid bone loss usually occurs in the first 6-12 months with a significant increase in fracture risk. This paper will provide an updated review on the possible pathogenesis of posttransplant osteoporosis and fractures, the natural history, and the current prevention and treatment strategies concerning different types of organ transplantation.

Citing Articles

Prevention and Rehabilitation After Heart Transplantation: A Clinical Consensus Statement of the European Association of Preventive Cardiology, Heart Failure Association of the ESC, and the European Cardio Thoracic Transplant Association, a Section....

Simonenko M, Hansen D, Niebauer J, Volterrani M, Adamopoulos S, Amarelli C Transpl Int. 2024; 37:13191.

PMID: 39015154 PMC: 11250379. DOI: 10.3389/ti.2024.13191.

Bone Loss after Solid Organ Transplantation: A Review of Organ-Specific Considerations.

Kim K, Ha J, Kim S, Kim J, Lee S, Choi H Endocrinol Metab (Seoul). 2024; 39(2):267-282.

PMID: 38693817 PMC: 11066446. DOI: 10.3803/EnM.2024.1939.

Increase in lumbar spine but not distal radius bone mineral density in adults after pancreas kidney transplantation.

Kratochvilova S, Maratova K, Sumnik Z, Brunova J, Hlavka Z, Girman P Bone Rep. 2024; 21:101764.

PMID: 38681747 PMC: 11046242. DOI: 10.1016/j.bonr.2024.101764.

Pharmacological prevention of bone loss and fractures following solid organ transplantations: Protocol for a systematic review and network meta-analysis.

Deng J, Moskalyk M, Hou W, Zuo Q, Luo J PLoS One. 2024; 19(4):e0302566.

PMID: 38669283 PMC: 11051654. DOI: 10.1371/journal.pone.0302566.

MicroRNA Expression Profile in Patients Admitted to ICU as Novel and Reliable Approach for Diagnostic and Therapeutic Purposes.

Yan Y, Liao L Mol Biotechnol. 2023; 66(6):1357-1375.

PMID: 37314613 DOI: 10.1007/s12033-023-00767-2.

References

Muchmore J, Cooper D, Ye Y, Schlegel V, ZUHDI N . Loss of vertebral bone density in heart transplant patients. Transplant Proc. 1991; 23(1 Pt 2):1184-5. View

Loke Y, Cavallazzi R, Singh S . Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax. 2011; 66(8):699-708. DOI: 10.1136/thx.2011.160028. View

Clarke B . Corticosteroid-induced osteoporosis: an update for dermatologists. Am J Clin Dermatol. 2012; 13(3):167-90. DOI: 10.2165/11594250-000000000-00000. View

Reed R, Wise R, Dobs A, Lechtzin N, Girgis R . Elevated HDL cholesterol levels are associated with osteoporosis in lung transplant candidates with chronic obstructive pulmonary disease. Respir Med. 2010; 104(12):1943-50. DOI: 10.1016/j.rmed.2010.08.004. View

Wang H, Chang P, Chu S, Liu K, Lai P, Huang J . Osteoporosis after kidney transplantation: preliminary report from a single center. Transplant Proc. 2008; 40(7):2412-3. DOI: 10.1016/j.transproceed.2008.06.042. View

Yeo H, Beck L, McDonald J, Zayzafoon M . Cyclosporin A elicits dose-dependent biphasic effects on osteoblast differentiation and bone formation. Bone. 2007; 40(6):1502-16. PMC: 1974856. DOI: 10.1016/j.bone.2007.02.017. View

Huang W, Lee S, Weng C, Lai P . Use of alendronate sodium (Fosamax) to ameliorate osteoporosis in renal transplant patients: a case-control study. PLoS One. 2012; 7(11):e48481. PMC: 3502459. DOI: 10.1371/journal.pone.0048481. View

Sokhi R, Anantharaju A, Kondaveeti R, Creech S, Islam K, Van Thiel D . Bone mineral density among cirrhotic patients awaiting liver transplantation. Liver Transpl. 2004; 10(5):648-53. DOI: 10.1002/lt.20104. View

Maggi S, Siviero P, Gonnelli S, Schiraldi C, Malavolta N, Nuti R . Osteoporosis risk in patients with chronic obstructive pulmonary disease: the EOLO study. J Clin Densitom. 2009; 12(3):345-52. DOI: 10.1016/j.jocd.2009.05.003. View

10.

Stempfle H, Werner C, Echtler S, Assum T, Meiser B, Angermann C . Rapid trabecular bone loss after cardiac transplantation using FK506 (tacrolimus)-based immunosuppression. Transplant Proc. 1998; 30(4):1132-3. DOI: 10.1016/s0041-1345(98)00181-x. View

11.

Monegal A, Navasa M, Guanabens N, Peris P, Pons F, Martinez de Osaba M . Bone disease after liver transplantation: a long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics. Osteoporos Int. 2001; 12(6):484-92. DOI: 10.1007/s001980170094. View

12.

Eileen Hay J . Osteoporosis in liver diseases and after liver transplantation. J Hepatol. 2003; 38(6):856-65. DOI: 10.1016/s0168-8278(03)00143-0. View

13.

Rossini M, Orsolini G, Viapiana O, Adami S, Gatti D . Bisphosphonates in the treatment of glucocorticoid-induced osteoporosis: pros. Endocrine. 2015; 49(3):620-7. DOI: 10.1007/s12020-014-0506-5. View

14.

Cueto-Manzano A, Konel S, Hutchison A, Crowley V, France M, Freemont A . Bone loss in long-term renal transplantation: histopathology and densitometry analysis. Kidney Int. 1999; 55(5):2021-9. DOI: 10.1046/j.1523-1755.1999.00445.x. View

15.

Durieux S, Mercadal L, Orcel P, Dao H, Rioux C, Bernard M . Bone mineral density and fracture prevalence in long-term kidney graft recipients. Transplantation. 2002; 74(4):496-500. DOI: 10.1097/00007890-200208270-00011. View

16.

Luo L, Shi Y, Bai Y, Zou Y, Cai B, Tao Y . Impact of tacrolimus on bone metabolism after kidney transplantation. Int Immunopharmacol. 2012; 13(1):69-72. DOI: 10.1016/j.intimp.2012.03.019. View

17.

van Staa T, Leufkens H, Abenhaim L, Zhang B, Cooper C . Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000; 15(6):993-1000. DOI: 10.1359/jbmr.2000.15.6.993. View

18.

Romero D, Buchinsky F, Rucinski B, Cvetkovic M, Bryer H, Liang X . Rapamycin: a bone sparing immunosuppressant?. J Bone Miner Res. 1995; 10(5):760-8. DOI: 10.1002/jbmr.5650100513. View

19.

Evenepoel P, Meijers B, de Jonge H, Naesens M, Bammens B, Claes K . Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation. Clin J Am Soc Nephrol. 2008; 3(6):1829-36. PMC: 2572285. DOI: 10.2215/CJN.01310308. View

20.

Park K, Hay J, Lee S, Lee Y, Wiesner R, Porayko M . Bone loss after orthotopic liver transplantation: FK 506 versus cyclosporine. Transplant Proc. 1996; 28(3):1738-40. View